EZH2: From Oncogenic Driver to Therapeutic Target for Overcoming Drug Resistance in Hepatocellular Carcinoma
Weijing Tang, Jianzhong Cao, Nan Wang, Liwen Tang, Jianxiong Cao · 2025
Read EZH2: From Oncogenic Driver to Therapeutic Target for Overcoming Drug Resistance in Hepatocellular Carcinoma by Weijing Tang, Jianzhong Cao, Nan Wang, Liwen Tang, Jianxiong Cao (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12766640.txt.
Description
Weijing Tang and four co-authors review a gene switch that helps liver cancer shrug off drugs in a 2025 paper. The switch, a protein called EZH2, tags genes to silence them and runs too hot in many liver tumors. That heat drives resistance to chemo, targeted drugs, and immune therapy alike.
The review maps how the switch keeps tumor cells alive: it bends cell cycle checks, blocks cell suicide, speeds DNA repair, and cools the immune scene around the tumor. Drugs that block the switch, from approved agents to new protein shredders, may re-sensitize tumors. Pairing those blockers with standard care is the path ahead.
Catalog record
| CREATOR | Weijing Tang, Jianzhong Cao, Nan Wang, Liwen Tang, Jianxiong Cao |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |